<DOC>
	<DOCNO>NCT00728494</DOCNO>
	<brief_summary>Enrolled patient recruit two parallel group therapy Hepatitis C. Patients first one receive patient assistance program , patient second group . All patient receive PegIntron Rebetol accord label .</brief_summary>
	<brief_title>Compliance HCV Genotype 1 Infected Patients Receiving PegIntron/Rebetol Patient Assistance Program ( Study P04671 )</brief_title>
	<detailed_description>Non-Probability Sample , Commercial product use accord EU label .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>According PegIntron/Rebetol label . Only HCV genotype 1 infected patient enrol study . According PegIntron/Rebetol label .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>